Table 4 Performance of the spectral, clinical and composite models to diagnose MASH in women.
Population | Group | model | n | n MASH | AUC | Threshold | Se | Sp | PPV | NPV | ACC | LR + | LR- | Youden statistic |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Women | Training | spectral | 147 | 21 | 0.83 (0.73–0.91) | 86 (71–100) | 81 (74–87) | 43 (33–55) | 97 (94–100) | 82 (74–88) | 4.51 (3–7.38) | 0.18 (0–0.37) | 0.67 (0.50–0.82) | |
Validation | 70 | 10 | 0.82 (0.67–0.95) | 70 (40–90) | 75 (63–85) | 32 (19–47) | 94 (88–98) | 74 (64–84) | 2.8 (1.41–5.33) | 0.4 (0.11–0.84) | 0.45 (0.12–0.73) | |||
Training | Clinical (age and ALT) | 147 | 21 | 0.85 (0.76–0.93) | 0.1689 | 86 (71–100) | 79 (71–86) | 40 (32_50) | 97 (94–100) | 80 (73–86) | 4 (2.77–6) | 0.18 (0–0.40) | 0.64 (0.47–0.79) | |
Validation | 69 | 10 | 0.85 (0.70–0.97) | 80 (50–100) | 75 (63–85) | 35 (24–50) | 96 (90–100) | 75 (65–85) | 3.15 (1.86–5.80) | 0.27 (0–0.65) | 0.55 (0.25–0.79) | |||
Training | Multivariate (spectral score + age + ALT) | 147 | 21 | 0.90 (0.81–0.96) | 0.2162 | 90 (76–100) | 88 (81–94) | 56 (44–69) | 98 (95–100) | 88 (82–93) | 7.60 (4.75–13.5) | 0.11 (0–0.28) | 0.79 (0.62–0.90) | |
Validation | 69 | 10 | 0.87 (0.71–0.98) | 80 (50–100) | 85 (75–93) | 47 (33–67) | 96 (91–100) | 84 (75–93) | 5.23 (2.9–11.8) | 0.24 (0–0.58) | 0.65 (0.36–0.90) |
